- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04133454
Evaluation of Safety and Tolerability of Libella Gene Therapy for Alzheimer's Disease: AAV- hTERT
Evaluation of Safety and Tolerability of Libella Gene Therapy (LGT) for Alzheimer's Disease: AAV- hTERT
Using gene therapy to express active telomerase (hTERT) in human cells has the potential to treat many neurodegenerative diseases related to aging, including Alzheimer's disease (AD).
This study will entail treating subjects with hTERT delivered via transduction using AAV. The goal is to extend the telomeres to prevent, delay, or even reverse the development of the pathology of AD. It is expected to have a direct consequence on cognitive function and quality of life in patients with neurodegenerative diseases, such as AD.
Study Overview
Detailed Description
Patients diagnosed with AD who meet with the inclusion - exclusion criteria, will be treated with a single dose of LGT delivered intravenously (IV) and intrathecally (IT).
Baseline will be performed within 8 weeks of beginning the treatment regimen. The treatment regimen will begin with IV delivery of AAV-hTERT, defined as "Day 0." Safety and efficacy analyses will be conducted at Weeks 1, 4, 13, 26, 39, and 52 post-treatment.
Study objectives
Primary: Safety and Tolerability
1. Investigate the safety and tolerability of AAV-hTERT by IV and IT administration.
Secondary: Provisional Efficacy
- Investigate LGT's ability to deliver hTERT to human cells and lengthen telomeres.
- Investigate the effects of lengthening telomeres on AD.
- Investigate other benefits provided by lengthening telomeres.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Jeff Mathis, PhD
- Phone Number: 1 785 4100223
- Email: jmathis@libellagt.com
Study Contact Backup
- Name: Osvaldo Martinez-Clark
- Phone Number: 1 786 4717814
- Email: ozclark@libellagt.com
Study Locations
-
-
Cundinamarca
-
Zipaquirá, Cundinamarca, Colombia, 250251
- Recruiting
- IPS Arcasalud SAS
-
Contact:
- Wiston Pernet, MD
- Phone Number: 57 3006840951
- Email: wirapeca@gmail.com
-
Principal Investigator:
- Jorge Ulloa, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
Subjects must meet the following inclusion criteria at the screening visit.
- Age of 45 years or older.
- Clinical diagnosis of Alzheimer's disease or early signs of dementia.
- Subjects, or their authorized representatives, must be adequately informed and understand the nature and risks of the study and must be able to provide a signature and date in the Informed Consent Form (ICF).
- Women must undergo a negative serum pregnancy test at the screening assessment.
- Subjects, or their representatives, must be able to communicate effectively with the study staff.
- Subjects, or their authorized representatives, must certify that they are able and willing to follow all protocol requirements and study restrictions.
Exclusion Criteria
Subjects are not eligible for the study if they meet any of the following criteria at the screening visit, unless otherwise specified.
- Subjects who have a history of allergy, hypersensitivity, or intolerance to any medications, components, or excipients of the investigational product, which cannot be resolved by the staff conducting the study.
- Female subjects who are pregnant, expected to become pregnant, or lactating/nursing.
- Subjects who are sexually active and who are unwilling or unable to use a method of effective contraception (e.g., hormonal and/or barrier) during their participation in the study.
- Subjects who are intolerant of, or do not wish to receive, IV or IT injections.
- Subjects who are currently alcoholics and/or use psychoactive substances.
- Subjects who cannot tolerate venipuncture and/or venous access.
- Subjects who have donated or had a significant loss of whole blood (480 ml or more) within 30 days, or donated plasma or platelets within 14 days prior to screening.
- Subjects who have received blood or blood products within 30 days prior to screening.
- Subjects who have been treated with another research product 30 days prior to the screening assessment, or plan to participate in another clinical trial, while in this study if in the opinion of the principal investigator, may place the subject at risk due to participation in the study, or may influence the results of the study or the subject's ability to complete the study. If more than 30 days have passed since participation in another clinical trial, the study staff must ensure that the subject has recovered from any adverse event (AE) associated with the research product used.
- Subjects who have a history or evidence of active infection or febrile illness within 7 days prior to the screening assessment.
- Subjects who have a history of any other clinically significant disease or disorder that, in the opinion of the principal investigator, may place the subject at risk due to participation in the study, or may influence the results of the study or the subject's ability to complete the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: subjects treated with LGT
subjects will be treated with a single dose of LGT (AAV-hTERT)
|
subjects will receive a single LGT (AAV-hTERT) treatment via IV and IT administration
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse events
Time Frame: 12 months
|
Incidence of serious adverse events and adverse events throughout the study
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
hTERT expression and telomerase activity
Time Frame: 12 months
|
Change from baseline of the telomere length
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jorge Ulloa, MD, IPS Arcaslud SAS
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Libella CO-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
Capital Medical UniversityPeking University First Hospital; The First Affiliated Hospital of Anhui Medical... and other collaboratorsRecruitingAlzheimer Disease | Familial Alzheimer Disease (FAD)China
-
University of PennsylvaniaNational Institute on Aging (NIA)CompletedDementia | Alzheimer Disease, At Risk | Alzheimer Disease, Protection AgainstUnited States
-
Kyoto UniversityOsaka University; Mie University; Tokushima University; Tokyo Metropolitan Geriatric... and other collaboratorsCompletedFamilial Alzheimer Disease (FAD) | PSEN1 MutationJapan
-
National Taiwan Normal UniversityCompletedAlzheimer Disease 2 Due to Apoe4 IsoformTaiwan
-
University of ArizonaNational Institute on Aging (NIA); University of Southern California; Syneos... and other collaboratorsRecruitingNeurodegenerative Diseases | Alzheimer Dementia | Late Onset Alzheimer DiseaseUnited States
-
Northwell HealthRecruitingAlzheimer Disease | Alzheimer Disease With Delusions | Alzheimer Disease With PsychosisUnited States
-
University of Kansas Medical CenterNational Institute on Aging (NIA)CompletedHealthy Aging | Alzheimer Disease 2 Due to Apoe4 IsoformUnited States
Clinical Trials on AAV-hTERT
-
Libella Gene TherapeuticsUnknown
-
Libella Gene TherapeuticsUnknownEvaluation of Safety and Tolerability of Libella Gene Therapy for Critical Limb Ischemia: AAV- hTERTCritical Limb IschemiaColombia
-
MeiraGTx UK II LtdSyne Qua Non Limited; EMAS PharmaActive, not recruitingAchromatopsiaUnited Kingdom, United States
-
Terence FlotteMassachusetts General Hospital; University of Massachusetts, WorcesterActive, not recruitingTay-Sachs Disease | Sandhoff DiseaseUnited States
-
MeiraGTx UK II LtdCompletedLeber Congenital AmaurosisUnited Kingdom, United States
-
MeiraGTx UK II LtdSyne Qua Non Limited; EMAS PharmaCompleted
-
Abramson Cancer Center of the University of PennsylvaniaCompleted
-
MeiraGTx UK II LtdSyne Qua Non LimitedCompletedEye Diseases | Retinal Diseases | Eye Diseases, Hereditary | Leber Congenital Amaurosis (LCA)United States, United Kingdom
-
National Eye Institute (NEI)Active, not recruiting
-
University of FloridaWithdrawnMetastatic Prostate Cancer